Catalyst Biosciences Inc (CBIO)


Stock Price Forecast

Oct. 30, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Catalyst Biosciences Inc chart...

About the Company

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.

CEO

Nassim Usman

Exchange

NASDAQ

$11M

Total Revenue

35

Employees

$19M

Market Capitalization

-6.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CBIO News

Catalyst Biosciences Inc ()

1mon ago, source: Insider Monkey

In this article, we will look at the 25 easiest and best paying jobs of 2024. We have also discussed the industrial and sectoral growth in the US.

Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time

12d ago, source: Seeking Alpha

Gyre Therapeutics is an under-the-radar biotech company that achieved its listing on the Nasdaq through a merger between ...

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Business Insider

Completed business combination with GNI Group Ltd. In October 2023, Gyre (formerly known as Catalyst Biosciences, Inc. (“Catalyst”)) completed the previously announced business combination wit ...

Protease medicines to catalyse change in complement-targeting therapies

2y ago, source: Nature

Catalyst Biosciences is a research and clinical development biopharmaceutical company focusing on rare disorders of the complement or coagulation systems. Catalyst’s approach builds on the ...

Building Connections: Blue Hen Executive Network

21d ago, source: University of Delaware

Grant Blouse, AS93, vice president of Catalyst Biosciences, Inc., enjoyed the interaction with his fellow alumni and appreciated hearing more about how he can become more engaged with his alma mater. ...

Why Root Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

10mon ago, source: Hosted on MSN

Evelo Biosciences, Inc. (NASDAQ: EVLO) fell 8.4% to $0.1465 in pre-market trading after dropping 9% on Wednesday. Catalyst Biosciences, Inc. (NASDAQ: CBIO) shares dropped 8.3% to $0.32 in pre ...

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

7d ago, source:

Caribou Biosciences, Inc. expects promising phase 1 studies on CB-010 and CB-011 for various lymphoma and myeloma treatments ...

Milestone Scientific Stock (AMEX:MLSS), Quotes and News Summary

1mon ago, source: Benzinga.com

Howmet Aerospace shares fell 0.1% to close at $45.98 on Friday. Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has ...

Sagimet Biosciences Inc. (SGMT)

6d ago, source: Yahoo Finance

March 27, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet ... its participation in the First Annual Goldman Sachs Catalyst Clinic. Management is scheduled to participate in a virtual ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call Transcript

24d ago, source: Hosted on MSN

Arcadia Biosciences, Inc. (NASDAQ:RKDA ... These success stories by category will be the catalyst for expanded distribution in 2025 and beyond. And GoodWheat has recently received many accolades ...

Catalyst Biosciences

1y ago, source: Statista

Catalyst Biosciences was founded in 1997 and operates in Wilmington, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100).

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...